(RTTNews) - Tuesday, Prelude Therapeutics Incorporated (PRLD) announced a clinical trial collaboration with Eli Lilly (LLY) to evaluate PRT13722 in combination with Verzenio (abemaciclib) and Inluriyo (imlunestrant) in patients with HR+/HER2- breast cancer.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.